Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Core Insights - ImmunityBio, Inc. reported a significant increase in product revenue for the third quarter of 2025, reaching $31.8 million, which is a 434% increase compared to $6.0 million in the same quarter of 2024 [1] Financial Performance - The product revenue growth is attributed to the continued commercial traction of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) [1]